Syntax Research, Inc. Crispr Therapeutics Ag Transaction History
Syntax Research, Inc.
- $126 Billion
- Q2 2024
A detailed history of Syntax Research, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Syntax Research, Inc. holds 250 shares of CRSP stock, worth $11,597. This represents 0.01% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$11,597
Previous $17 Million
20.76%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
510Shares Held
57.4MCall Options Held
1.74MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$365 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$348 Million3.35% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$146 Million0.13% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$146 Million1.99% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$129 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.62B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....